Francesco Maria Lavino appointed CEO of F2G Ltd

pharmafile | April 27, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

F2G Limited has announced that Francesco Maria Lavino has been appointed Chief Executive Officer and member of the Board of F2G.

F2G is a clinical-stage biopharmaceutical company focused on life threatening fungal diseases. Lavino has expertise in the antifungal arena, serving as AVP, Global Brand Leader in the anti-infectives portfolio at Merck & Co. and as Chief Commercial Officer of Nabriva Therapeutics.

Ian Nicholson is stepping down as CEO, after eight years with F2G, to pursue non-executive roles and will provide support to ensure an effective transition.

Patrick Vink, Chairman of F2G, commented: “We are delighted to welcome Francesco Lavino to F2G. He is a highly experienced leader with a proven track record of working to create significant value for shareholders. We believe we have a strong team in place to lead F2G into its next phase of growth.”

Related Content

No items found

Latest content